000919 Stock Overview
Manufactures and sells pharmaceutical products and medical devices in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Jinling Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.74 |
| 52 Week High | CN¥8.24 |
| 52 Week Low | CN¥5.38 |
| Beta | 0.47 |
| 1 Month Change | -2.03% |
| 3 Month Change | 12.71% |
| 1 Year Change | -13.37% |
| 3 Year Change | -10.13% |
| 5 Year Change | -6.26% |
| Change since IPO | -19.23% |
Recent News & Updates
Shareholder Returns
| 000919 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -10.8% | -1.9% | -1.2% |
| 1Y | -13.4% | -1.8% | 11.8% |
Return vs Industry: 000919 underperformed the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 000919 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 000919 volatility | |
|---|---|
| 000919 Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 000919 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000919's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 4,871 | n/a | jlyy1999.com |
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products and medical devices in China. The company provides Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, polyarteritis, acute arterial embolism of extremities, diabetic gangrene, intravenous thrombus, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; lentinan injection for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of wound hemostasis. It also offers medical and health care services.
Jinling Pharmaceutical Company Limited Fundamentals Summary
| 000919 fundamental statistics | |
|---|---|
| Market cap | CN¥4.20b |
| Earnings (TTM) | CN¥73.41m |
| Revenue (TTM) | CN¥2.90b |
57.3x
P/E Ratio1.4x
P/S RatioIs 000919 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000919 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.90b |
| Cost of Revenue | CN¥2.32b |
| Gross Profit | CN¥586.36m |
| Other Expenses | CN¥512.95m |
| Earnings | CN¥73.41m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 20.21% |
| Net Profit Margin | 2.53% |
| Debt/Equity Ratio | 0% |
How did 000919 perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield77%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 02:28 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jinling Pharmaceutical Company Limited is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jessica Li | BofA Global Research |
| Han Wei Yu | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Weina Jiang | Everbright Securities Co. Ltd. |